Summary:
- Syngenis, a biotechnology company, has secured a significant R&D tax incentive refund from the Australian government to support its ongoing research and development initiatives.
- The funding will be utilized to accelerate the company's laboratory expansion and technical infrastructure, specifically focusing on the advancement of its proprietary cell-based therapeutic platforms.